In humans, one study found that subjects who respond to ketamine treatment for depression show higher levels of BDNF (24 h after administration) than non-responders and that there was a negative correlation between BDNF levels and Montgomery-Asberg Depression Rating Scale (MADRS) score (Haile et al., 2014). This evidence concerns the gene BDNF and depressive symptom measurement.